Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Devimistat - Rafael Pharmaceuticals

Drug Profile

Devimistat - Rafael Pharmaceuticals

Alternative Names: 6,8-bis(benzylthio)octanoic-acid; Bylantra; CPI-613®

Latest Information Update: 09 Aug 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cornerstone Pharmaceuticals; Stony Brook University
  • Developer Case Comprehensive Cancer Center; Cornerstone Pharmaceuticals; IQVIA; National Cancer Institute (USA); Rafael Pharmaceuticals; Wake Forest University Health Sciences; Wake Forest University School of Medicine
  • Class Antineoplastics; Carboxylic acids; Coenzymes; Fatty acids; Small molecules; Sulfides
  • Mechanism of Action Ketoglutarate dehydrogenase complex inhibitors; Pyruvate dehydrogenase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Burkitt's lymphoma; Acute myeloid leukaemia; Pancreatic cancer; Peripheral T-cell lymphoma; T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Pancreatic cancer
  • Phase II B-cell lymphoma; Burkitt's lymphoma; Myelodysplastic syndromes; Small cell lung cancer; Solid tumours
  • Phase I/II Cancer
  • Phase I Colorectal cancer; Hodgkin's disease; Non-Hodgkin's lymphoma
  • No development reported Biliary cancer

Most Recent Events

  • 18 Jul 2019 Phase-III clinical trials in Pancreatic cancer (Late-stage disease, Metastatic disease, First-line therapy, Combination therapy) in Israel (IV)
  • 26 Jun 2019 Devimistat licensed to Ono Pharmaceuticals in Japan, South Korea, Taiwan and ASEAN countries
  • 05 Jun 2019 Wake Forest University Health Sciences and National Cancer Institute complete a phase I trial in T-cell non-Hodgkin's lymphoma and Hodgkin's disease in USA, prior to June 2019 (NCT02168140)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top